[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540033":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":146,"collaborators":26,"id":148,"slug":26,"hasResults":149,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":26,"eligibilityCriteria":153,"healthyVolunteers":149,"sex":154,"minAge":155,"maxAge":26,"enrollmentInfo":156,"targetDuration":26,"studyType":159,"phases":160,"briefSummary":162,"conditions":163,"keywords":26,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},{"fullName":5,"class":6},"Johnson & Johnson Enterprise Innovation Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Dose Escalation","EXPERIMENTAL","Participants with advanced solid tumors will receive JNJ-87704916 alone and in combination with cetrelimab. Ascending dose levels will be sequentially tested.",[13,14],"Drug: JNJ-87704916","Drug: Cetrelimab",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 2: Dose Expansion","Part 2 will consist of three cohorts: Cohort A, B and C. Participants in cohort A\\&B with metastatic non-small cell lung cancer (NSCLC) will receive JNJ-87704916 in combination with cetrelimab at the dose identified in Part 1. Cohort C will evaluate JNJ-87704916 treatment in combination with ongoing Standard of care (SoC) PD(L)-1 antibody therapy in frontline treatment of NSCLC.",[13,14,19],"Drug: Standard of Care PD(L)-1",[21,27,33],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","JNJ-87704916","JNJ-87704916 will be administered as an intratumoral injection.",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Cetrelimab","Cetrelimab will be administered.",[9,16],[32],"JNJ-63723283",{"type":22,"name":34,"description":35,"armGroupLabels":36,"otherNames":26},"Standard of Care PD(L)-1","Frontline anti-PD(L)-1 antibody therapy will be administered as standard of care treatment.",[16],[38],{"name":39,"affiliation":5,"role":40},"Johnson & Johnson Enterprise Innovation Inc Clinical Trial","STUDY_DIRECTOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":26,"email":46},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[48,60,71,80,90,101,111,121,131,140],{"facility":49,"status":50,"city":51,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":26},"NYU Langone Health","RECRUITING","New York","10016","United States",{"type":55,"coordinates":56},"Point",[57,58],-74.00597,40.71427,{"lat":58,"lon":57},{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":53,"cosmosGeoPoint":66,"geoPoint":70,"contacts":26},"Fox Chase Cancer Center","SUSPENDED","Philadelphia","Pennsylvania","19111",{"type":55,"coordinates":67},[68,69],-75.16362,39.95238,{"lat":69,"lon":68},{"facility":72,"status":50,"city":73,"state":64,"zip":74,"country":53,"cosmosGeoPoint":75,"geoPoint":79,"contacts":26},"UPMC Cancer Centers","Pittsburgh","15232",{"type":55,"coordinates":76},[77,78],-79.99589,40.44062,{"lat":78,"lon":77},{"facility":81,"status":50,"city":82,"state":83,"zip":84,"country":53,"cosmosGeoPoint":85,"geoPoint":89,"contacts":26},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":55,"coordinates":86},[87,88],-95.36327,29.76328,{"lat":88,"lon":87},{"facility":91,"status":50,"city":92,"state":93,"zip":94,"country":95,"cosmosGeoPoint":96,"geoPoint":100,"contacts":26},"Toronto General Hospital","Toronto","Ontario","M5G 2C4","Canada",{"type":55,"coordinates":97},[98,99],-79.39864,43.70643,{"lat":99,"lon":98},{"facility":102,"status":50,"city":103,"state":104,"zip":105,"country":95,"cosmosGeoPoint":106,"geoPoint":110,"contacts":26},"Centre Hospitalier de l'Universite de Montreal","Montreal","Quebec","H2X 0A9",{"type":55,"coordinates":107},[108,109],-73.58781,45.50884,{"lat":109,"lon":108},{"facility":112,"status":50,"city":113,"state":26,"zip":114,"country":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":26},"Gustave Roussy","Villejuif","94805","France",{"type":55,"coordinates":117},[118,119],2.35992,48.7939,{"lat":119,"lon":118},{"facility":122,"status":50,"city":123,"state":26,"zip":124,"country":125,"cosmosGeoPoint":126,"geoPoint":130,"contacts":26},"Hosp Univ Vall D Hebron","Barcelona","08035","Spain",{"type":55,"coordinates":127},[128,129],2.15899,41.38879,{"lat":129,"lon":128},{"facility":132,"status":50,"city":133,"state":26,"zip":134,"country":125,"cosmosGeoPoint":135,"geoPoint":139,"contacts":26},"Hosp Univ Fund Jimenez Diaz","Madrid","28040",{"type":55,"coordinates":136},[137,138],-3.70256,40.4165,{"lat":138,"lon":137},{"facility":141,"status":50,"city":133,"state":26,"zip":142,"country":125,"cosmosGeoPoint":143,"geoPoint":145,"contacts":26},"Hosp Univ Hm Sanchinarro","28050",{"type":55,"coordinates":144},[137,138],{"lat":138,"lon":137},{"type":147,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100540033",false,"NCT06311578","A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors","Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors","Inclusion Criteria:\n\n* For Part 1: Individuals with a diagnosis of advanced or metastatic solid tumor exhausting all available standard of care therapy; Part 2: Individuals with histologically or cytologically confirmed metastatic or locally advanced NSCLC\n* Have at least 1 injectable tumor\n* Eastern cooperative oncology group (ECOG) performance status of grade 0 or 1\n* A participant who can have children must have a negative pregnancy test before the first dose of study treatment and during the study\n* Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy\n\nExclusion Criteria:\n\n* Active disease involvement of the CNS (example, primary central nervous system tumors, metastases, leptomeningeal disease). Some exceptions are allowed\n* Prior history of, or active, significant herpetic infections (example, herpetic keratitis or encephalitis) or active herpetic infections that require ongoing systemic anti-viral therapy\n* Active infection or condition that requires treatment with systemic anti-infective agents (example, antibiotics, antifungals, or antivirals) within 7 days prior to the first dose of study treatment or chronic use of anti-infective agents\n* History of solid organ or hematologic stem cell transplantation\n* Known positive test result for human immunodeficiency virus (HIV) or other immunodeficiency syndrome\n* History of allergy to protein-based therapies or history of any significant drug allergy (such as anaphylaxis, hepatotoxicity, or immune-mediated thrombocytopenia or anemia)","ALL","18 Years",{"count":157,"type":158},126,"ESTIMATED","INTERVENTIONAL",[161],"PHASE1","The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.",[164],"Neoplasms","2026-06-04",{"date":167,"type":168},"2026-06-05","ACTUAL",{"date":170,"type":168},"2024-04-10",{"date":172,"type":158},"2032-08-26",{"name":5,"class":6},10]